Get to know our clinical trials
Exploring the Anti-Aging Effects of Metformin in COPD
THE PRIMARY OBJECTIVES OF THIS STUDY ARE TO INVESTIGATE WHETHER TAKING METFORMIN SLOWS THE LOSS OF LUNG FUNCTION AND HALTS THE PROGRESSION OF EMPHYSEMA (LUNG DAMAGE). WE ALSO WANT TO EXPLORE WHETHER SOME OF THE CONDITIONS ASSOCIATED WITH AGING AND VERY COMMON IN PATIENTS WITH THIS DISEASE—SUCH AS CANCERS (ESPECIALLY LUNG CANCER), ANGINA, HEART ATTACKS, OR KIDNEY DAMAGE—CAN BE PREVENTED BY TAKING METFORMIN.
Technical Summary
- EXPLORING THE ANTI-AGING EFFECTS OF METFORMIN IN COPD
- Code EudraCT: 2025-520972-24
- Protocol number: AMICO
- Promoter: Instituto de Investigación Sanitaria de Navarra (IdiSNA)
- Molecule/Drug: Metformina
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.